took a while to even find any info on this again-n
Post# of 222
(Total Views: 286)
Posted On: 05/27/2018 10:26:29 PM
took a while to even find any info on this again-never seen a company listed on a us exchange -otc as BLOZF-without any info on such exchange and havent even found finances even on canadian exchanges searching by full name etc
anyway -i always bite my jaw when companies punish future shareholders by running these low priced pp and or option and warrant deals bc to me its always a constant draw on pps until the period of the options etc is over.
They have to hold pp shares obtained at 1.15 pps for either 6 or 12 months in the usa depending on whether sec filed- havent found that info -it seems like BLO-not blozf- news releases say or indicate this info is to be hidden from the us markert-never experienced this before -
but when pps jumped to 2.60 i thought that was ridiculous bc of the inevitable coming pull from pp holders who, when their apparent restriction period of 6 months was over (6 months from anywhere from Nov 17 to Dec 7 ,2017) would be selling into the market if the market pps was over 1.15 or even over 1.60- the latter a draw on pps for a full 3 years.
I shake my head my sometimes -almost as if the companies dont know the future price they and longs are paying for the companies present inducement to pp holders- but somebody has had to explain these games to the companies when the deals- the often desperate 'money now' fundraising deals are made.
Brokered Private Placement
Vancouver, British Columbia, December 7, 2017 – Cannabix Technologies Inc. (CSE: BLO) (the “Company”) is pleased to announce that it has closed its private placement of 4,000,000 units (“Units”) of the Company at a price of $1.15 per Unit (the “Offering Price”), for aggregate gross proceeds of $4.6 million (the “Offering”). Each Unit consists of one common share of the Company (a “Common Share”) and one common share purchase warrant, each warrant entitling the holder to purchase one additional Common Share at an exercise price of $1.60 for a period of three years following closing. The Offering was underwritten by Cormark Securities Inc. (the “Underwriter”), which exercised in full its option to purchase up to an additional 500,000 Units at the Offering Price.
In connection with the Offering, the Underwriter received a cash commission of $276,000 and 240,000 broker warrants (the “Broker Warrants”), each Broker Warrant entitling the holder to purchase one Unit at the Offering Price for a period of two years following closing.
In addition, the Company is pleased to announce that it has closed a concurrent non-brokered private placement (the “Concurrent Private Placement”) of 850,000 units at the Offering Price, for aggregate gross proceeds of $977,500. The units issued pursuant to the Concurrent Private Placement were issued on substantially the same terms as the Units issued under the Offering.
The Company intends to use the net proceeds from the Offering and the Concurrent Private Placement to fund research and development related to its cannabis breathalyzer technologies and for working capital and general corporate purposes.
All securities issued in connection with the Offering and the Concurrent Private Placement are subject to a statutory hold period expiring four months and one day after December 7, 2017.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state laws and may not be offered or sold in the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or unless an exemption from such registration is available.
Not For Distribution To U.S. Newswire Services Or Dissemination In The United States.
November 17, 2017
Cannabix Technologies Inc. Announces Upsize of Previously Announced Bought Deal Private Placement to and Concurrent Non-Brokered Private Placement
Vancouver, British Columbia, November 20, 2017 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) is pleased to announce that it has amended its agreement with Cormark Securities Inc. (the "Underwriter"
and has agreed to increase the size of its previously announced $3.45 million "bought deal" private placement offering. Pursuant to the upsized deal terms, the Underwriter has agreed to purchase, on a "bought deal” basis, 3,500,000 units ("Units" in the capital of the Company, at a price of $1.15 per Unit (the "Offering Price" for aggregate gross proceeds of $4,025,000 (the "Offering". Each Unit will consist of one common share (each a “Common Share”) of the Company and one Common Share purchase warrant of the Company. Each Common Share purchase warrant (a “Warrant”) will entitle the holder thereof to purchase one Common Share at a price equal to $1.60 per Common Share for a period of 36 months following closing of the Offering.
The Company has granted the Underwriter an option (“Underwriter’s Option”), exercisable in whole or in part at any time prior to the closing date of the Offering, to purchase up to an additional 500,000 Units at the Offering Price. In the event that the Underwriter’s Option is exercised in its entirety, the aggregate gross proceeds of the Offering shall be $4,600,000.
In addition, the Company intends to complete a concurrent non-brokered private placement of 850,000 Units at the Offering Price for aggregate gross proceeds of $977,500 (the "Concurrent Private Placement". The Units issuable pursuant to the Concurrent Private Placement will be on the same terms as those issuable pursuant to the Offering.
The Company intends to use the net proceeds from the Offering and Concurrent Private Placement for research and development purposes related to its cannabis breathalyzer technologies, working capital and general corporate purposes.
Closing of the Offering and Concurrent Private Placement is expected to occur on or about December 7, 2017 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the Canadian Securities Exchange and any applicable securities regulatory authorities.
This press release shall not constitute an offer to sell or solicitation of an offer to buy the securities in any jurisdiction. The common shares will not be and have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for account or benefit of, U.S. persons, absent registration or applicable exemption from the registration requirements. Any public offering of securities in the United States must be by means of a prospectus containing detailed information about the Company and management as well as financial statements.
Not For Distribution To U.S. Newswire Services Or Dissemination In The United States.
November 17, 2017
Cannabix Technologies Inc. Announces $3.45 Million Bought Deal Private Placement
Vancouver, British Columbia, November 17, 2017 -- Cannabix Technologies Inc. (CSE: BLO) (the “Company or Cannabix”) is pleased to announce that it has entered into an agreement with Cormark Securities Inc. (the “Underwriter”) pursuant to which the Underwriter has agreed to purchase 3,000,000 units (“Units”) of the Company on a bought deal private placement basis at a price of $1.15 per Unit (the “Offering Price”), for gross proceeds of $3.45 million (the “Offering”). Each Unit shall consist of one common share (a “Common Share”) of the Company and one common share purchase warrant. Each warrant will entitle the holder thereof to purchase one Common Share at a price equal to $1.60 for a period of 36 months following Closing.
In addition, the Company has granted the Underwriter an option to purchase up to an additional 15% of the Offering at the Offering Price exercisable, in whole or in part, at any time up the closing of the Offering.
The Offering is scheduled to close on December 7, 2017 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the Canadian Securities Exchange.
The Company intends to use the funds for research and development purposes related to its cannabis breathalyzer technologies, working capital and general corporate purposes.
This press release is not an offer or a solicitation of an offer of securities for sale in the United States. The securities described herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold in the United States unless registered under the U.S. Securities Act or unless an exemption from registration is available.
Not For Distribution To United Stated Newswire Services Or For Dissemination In The United States And Does Not Constitute An Offer In The United States Of The Securities Described Herein.
anyway -i always bite my jaw when companies punish future shareholders by running these low priced pp and or option and warrant deals bc to me its always a constant draw on pps until the period of the options etc is over.
They have to hold pp shares obtained at 1.15 pps for either 6 or 12 months in the usa depending on whether sec filed- havent found that info -it seems like BLO-not blozf- news releases say or indicate this info is to be hidden from the us markert-never experienced this before -
but when pps jumped to 2.60 i thought that was ridiculous bc of the inevitable coming pull from pp holders who, when their apparent restriction period of 6 months was over (6 months from anywhere from Nov 17 to Dec 7 ,2017) would be selling into the market if the market pps was over 1.15 or even over 1.60- the latter a draw on pps for a full 3 years.
I shake my head my sometimes -almost as if the companies dont know the future price they and longs are paying for the companies present inducement to pp holders- but somebody has had to explain these games to the companies when the deals- the often desperate 'money now' fundraising deals are made.
Brokered Private Placement
Vancouver, British Columbia, December 7, 2017 – Cannabix Technologies Inc. (CSE: BLO) (the “Company”) is pleased to announce that it has closed its private placement of 4,000,000 units (“Units”) of the Company at a price of $1.15 per Unit (the “Offering Price”), for aggregate gross proceeds of $4.6 million (the “Offering”). Each Unit consists of one common share of the Company (a “Common Share”) and one common share purchase warrant, each warrant entitling the holder to purchase one additional Common Share at an exercise price of $1.60 for a period of three years following closing. The Offering was underwritten by Cormark Securities Inc. (the “Underwriter”), which exercised in full its option to purchase up to an additional 500,000 Units at the Offering Price.
In connection with the Offering, the Underwriter received a cash commission of $276,000 and 240,000 broker warrants (the “Broker Warrants”), each Broker Warrant entitling the holder to purchase one Unit at the Offering Price for a period of two years following closing.
In addition, the Company is pleased to announce that it has closed a concurrent non-brokered private placement (the “Concurrent Private Placement”) of 850,000 units at the Offering Price, for aggregate gross proceeds of $977,500. The units issued pursuant to the Concurrent Private Placement were issued on substantially the same terms as the Units issued under the Offering.
The Company intends to use the net proceeds from the Offering and the Concurrent Private Placement to fund research and development related to its cannabis breathalyzer technologies and for working capital and general corporate purposes.
All securities issued in connection with the Offering and the Concurrent Private Placement are subject to a statutory hold period expiring four months and one day after December 7, 2017.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state laws and may not be offered or sold in the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or unless an exemption from such registration is available.
Not For Distribution To U.S. Newswire Services Or Dissemination In The United States.
November 17, 2017
Cannabix Technologies Inc. Announces Upsize of Previously Announced Bought Deal Private Placement to and Concurrent Non-Brokered Private Placement
Vancouver, British Columbia, November 20, 2017 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) is pleased to announce that it has amended its agreement with Cormark Securities Inc. (the "Underwriter"
and has agreed to increase the size of its previously announced $3.45 million "bought deal" private placement offering. Pursuant to the upsized deal terms, the Underwriter has agreed to purchase, on a "bought deal” basis, 3,500,000 units ("Units" in the capital of the Company, at a price of $1.15 per Unit (the "Offering Price" for aggregate gross proceeds of $4,025,000 (the "Offering". Each Unit will consist of one common share (each a “Common Share”) of the Company and one Common Share purchase warrant of the Company. Each Common Share purchase warrant (a “Warrant”) will entitle the holder thereof to purchase one Common Share at a price equal to $1.60 per Common Share for a period of 36 months following closing of the Offering. The Company has granted the Underwriter an option (“Underwriter’s Option”), exercisable in whole or in part at any time prior to the closing date of the Offering, to purchase up to an additional 500,000 Units at the Offering Price. In the event that the Underwriter’s Option is exercised in its entirety, the aggregate gross proceeds of the Offering shall be $4,600,000.
In addition, the Company intends to complete a concurrent non-brokered private placement of 850,000 Units at the Offering Price for aggregate gross proceeds of $977,500 (the "Concurrent Private Placement"
. The Units issuable pursuant to the Concurrent Private Placement will be on the same terms as those issuable pursuant to the Offering. The Company intends to use the net proceeds from the Offering and Concurrent Private Placement for research and development purposes related to its cannabis breathalyzer technologies, working capital and general corporate purposes.
Closing of the Offering and Concurrent Private Placement is expected to occur on or about December 7, 2017 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the Canadian Securities Exchange and any applicable securities regulatory authorities.
This press release shall not constitute an offer to sell or solicitation of an offer to buy the securities in any jurisdiction. The common shares will not be and have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for account or benefit of, U.S. persons, absent registration or applicable exemption from the registration requirements. Any public offering of securities in the United States must be by means of a prospectus containing detailed information about the Company and management as well as financial statements.
Not For Distribution To U.S. Newswire Services Or Dissemination In The United States.
November 17, 2017
Cannabix Technologies Inc. Announces $3.45 Million Bought Deal Private Placement
Vancouver, British Columbia, November 17, 2017 -- Cannabix Technologies Inc. (CSE: BLO) (the “Company or Cannabix”) is pleased to announce that it has entered into an agreement with Cormark Securities Inc. (the “Underwriter”) pursuant to which the Underwriter has agreed to purchase 3,000,000 units (“Units”) of the Company on a bought deal private placement basis at a price of $1.15 per Unit (the “Offering Price”), for gross proceeds of $3.45 million (the “Offering”). Each Unit shall consist of one common share (a “Common Share”) of the Company and one common share purchase warrant. Each warrant will entitle the holder thereof to purchase one Common Share at a price equal to $1.60 for a period of 36 months following Closing.
In addition, the Company has granted the Underwriter an option to purchase up to an additional 15% of the Offering at the Offering Price exercisable, in whole or in part, at any time up the closing of the Offering.
The Offering is scheduled to close on December 7, 2017 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the Canadian Securities Exchange.
The Company intends to use the funds for research and development purposes related to its cannabis breathalyzer technologies, working capital and general corporate purposes.
This press release is not an offer or a solicitation of an offer of securities for sale in the United States. The securities described herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold in the United States unless registered under the U.S. Securities Act or unless an exemption from registration is available.
Not For Distribution To United Stated Newswire Services Or For Dissemination In The United States And Does Not Constitute An Offer In The United States Of The Securities Described Herein.
(1)
(0)Cannabix Technologies Inc. (BLOZF) Stock Research Links
Scroll down for more posts ▼